Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics, Inc. (LENZ) Change in Accured Expenses (2022 - 2023)

LENZ Therapeutics (LENZ) has disclosed Change in Accured Expenses for 2 consecutive years, with $1.6 million as the latest value for Q4 2023.

  • On a quarterly basis, Change in Accured Expenses rose 256.73% to $1.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $7.8 million, a 601.17% increase, with the full-year FY2024 number at -$7.5 million, down 195.85% from a year prior.
  • Change in Accured Expenses was $1.6 million for Q4 2023 at LENZ Therapeutics, down from $3.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.3 million in Q3 2023 to a low of -$1.7 million in Q1 2022.